Journal of Clinical Oncology
Articles in this Issue
BiTEs vs. ICIs in lymphoma, leukemia, and myeloma: Which immunotherapy reigns supreme? A systematic review and meta-analysis.
e14524 Background: Hematologic malignancies, including leukemia, lymphoma, and myeloma, pose significant challenges due to their complex biology. Advances...
Evaluation of NCI Designated Cancer Centers medical student education and training initiatives.
9032 Background: The rising incidence of common cancers, an aging oncology workforce, and workforce shortages underscore the importance of medical educati...
In-hospital mortality and incidence trends for tumor lysis syndrome in the United States from 2016 to 2020, a National Inpatient Sample study.
e22536 Background: Tumor lysis syndrome (TLS) is an oncologic emergency characterized by metabolic disturbances that can lead to organ failure. The larges...
Intensive surveillance and aggressive multi-modal treatment for liver metastases from uveal melanoma.
9549 Background: We report utility of diagnostic laparoscopy and long-term survival outcome for patients undergoing multi-modal treatment for liver metast...
Long-term outcomes of CAR-T cell therapy in DLBCL.
e19004 Background: CAR T-cell therapy, which involves engineering a patient's T-cells with a chimeric antigen receptor (CAR) to target and eliminate cance...
Investigating the association of blood-to-tissue tumor mutation burden (TMB) ratio with overall survival and intratumor heterogeneity (ITH) in advanced NSCLC.
2565 Background: High tumor mutation burden (TMB) measured via tissue-based next-generation sequencing (NGS) (tTMB) has been shown to predict better survi...
Racial disparities in major adverse cardiovascular and cerebrovascular events and healthcare resource utilization in patients with pancreatic cancer.
e16466 Background: Pancreatic cancer is a lethal malignancy, and racial disparities in outcomes remain a major public health concern. Comorbidities such a...
Accelerating and de-risking late pre-clinical drug development with the zebrafish tumor xenograft (ZTX) platform.
e15111 Background: Insufficient drug efficacy due to patient response heterogeneity is the main reason why 19 of 20 oncology drug candidates fail during c...
Monitoring concordance with evidence-based guidelines in the treatment of stage I to IIIA lung cancer: A quality improvement initiative.
e23240 Background: The Commission on Cancer (CoC) Standard 7.2 mandates an in-depth analysis of cancer treatments to ensure concordance with national evid...
A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).
TPS11584 Background: Tenosynovial giant cell tumor (TGCT) is a rare, non-malignant, locally aggressive tumor of the synovium, primarily affecting knee, hi...
Plasma TP53 as an indicator of poor survival in neoadjuvant-treated triple negative breast cancer: A prospective study and meta-analysis.
e12594 Background: A proportion of triple negative breast cancer (TNBC) patients with pathologic complete response (pCR) will eventually experience diseas...
Bariatric surgery and risk of gastrointestinal and hormone-sensitive cancers in patients with metabolic-associated steatotic liver disease and obesity: A multicenter matched cohort study.
10547 Background: Metabolic-associated steatotic liver disease (MASLD) is strongly associated with an increased risk of hormone-sensitive and gastrointest...
Development and validation of a droplet digital PCR (ddPCR) assay to detect MGMT promoter methylation in FFPE tumors of glioblastoma (GBM) patients.
2072 Background: Methylation of the MGMT gene promoter (MGMTp) is a critical biomarker to inform GBM prognosis and guide treatment decisions, including cl...
Efficacy and safety of ipilimumab combination therapy in advanced hepatocellular carcinoma patients progressing after multiple lines of treatment: A retrospective multicenter study.
e16187 Background: The combination of nivolumab and ipilimumab has demonstrated significant antitumor activity in first-line treatment for hepatocellular...
Strength of evidence supporting cancer drug approvals in China, 2017-2021.
TPS11188 Background: Well-designed and adequately conducted clinical trials are the cornerstone evidence to demonstrate drug safety and efficacy and suppo...
Cadence of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC).
560 Background: Post-surgical detection of molecular residual disease (MRD) via plasma ctDNA testing is strongly associated with recurrence of eBC. Our pr...
Quality of life and lifestyle changes during and after therapy in women with endometrial cancer: A global study of 1,066 patients (NOGGO, ENGOT, GCIG, ENGAGe-IMPROVE/EXPRESSION XI).
5606 Background: Endometrial cancer (EC) affects many women worldwide, yet the impact of the disease and its treatment on symptoms, lifestyle and quality...
Impact of <i>Helicobacter pylori</i> infection on molecular alterations and immune dynamics in gastric cancer.
2626 Background: Helicobacter pylori (HP) infection, a major risk factor for gastric cancer (GC), modulates tumor immunity. Evidence indicates...
Considering the caregiver in early-phase clinical trials.
e13899 Background: Patients enrolled in early-phase clinical trials (EP-CTs) often rely on family and friends for caregiving support. In these settings, i...
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial.
TPS2102 Background: Meningiomas are the most common intracranial tumors. Standard treatment involves surgical resection with curative intent. When gross t...
Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.
7015 Background: Glofitamab, a CD20:CD3 bispecific antibody, has shown durable responses as fixed duration monotherapy in...
The clinical trials landscape in follicular lymphoma: A systematic review.
e23016 Background: Follicular lymphoma (FL) is an incurable B-cell lymphoma, with advances in therapy leading to a median overall survival (OS) exceeding...
A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor γδ T cell therapy, in relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC).
TPS4613 Background: CD70 is a type II transmembrane protein of the tumor necrosis factor superfamily normally transiently expressed in activated lymphocyt...
First safety analysis of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluoruracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
4172 Background: Aim of the prospective single arm HOLIPANC trial (NCT04617457) is to evaluate the efficacy and safety of multimodal treatment in pancreat...
Comparison of induction chemoimmunotherapy with surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: A retrospective study.
e20050 Background: Despite the promising potential of neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC), there is limited consensus on...